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Membrane heparan sulfate proteoglycans (HSPG) regulate cell proliferation, migration,
and differentiation and are therefore considered key players in cancer cell development
processes. Here, we used the NT4 peptide to investigate how the sulfation pattern
of HSPG on cells drives binding specificity. NT4 is a branched peptide that binds
the glycosaminoglycan (GAG) chains of HSPG. It has already been shown to inhibit
growth factor-induced migration and invasiveness of cancer cells, implying antagonist
binding of HSPG. The binding affinity of NT4 with recombinant HSPG showed that
NT4 bound glypican-3 and -4 and, with lower affinity, syndecan-4. NT4 binding to
the cancer cell membrane was inversely correlated with sulfatase expression. NT4
binding was higher in cell lines with lower expression of SULF-1 and SULF-2, which
confirms the determinant role of sulfate groups for recognition by NT4. Using 8-mer and
9-mer heparan sulfate (HS) oligosaccharides with analog disaccharide composition and
different sulfation sites, a possible recognition motif was identified that includes repeated
6-O-sulfates alternating with N- and/or 2-O-sulfates. Molecular modeling provided a fully
descriptive picture of binding architecture, showing that sulfate groups on opposite sides
of the oligosaccharide can interact with positive residues on two peptide sequences
of the branched structure, thus favoring multivalent binding and explaining the high
affinity and selectivity of NT4 for highly sulfated GAGs. NT4 and possibly newly selected
branched peptides will be essential probes for reconstructing and unraveling binding sites
for cancer-involved ligands on GAGs and will pave the way for new cancer detection and
treatment options.
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INTRODUCTION
Heparan sulfate proteoglycans (HSPG) are a large family of heterogeneous molecules found in
the extracellular matrix (ECM) and on the membranes of vertebrate cells. They are composed
of a protein linked to sulfated glycosaminoglycan (GAG) chains, which are linear polymers of
repeated disaccharide units consisting of an amino sugar and uronic acid, that can be modified
with sulfate groups at various positions. HSPG can be classified by their localization as extracellular,
intracellular, pericellular, and cell surface associated. Cell surface HSPG include the two families
of syndecans and glypicans and betaglycan, a transmembrane proteoglycan (PG) with heparan
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and chondroitin sulfate chains. Glycosaminoglycan moieties in
membrane-associated HSPG do not differ much in saccharide
composition but are very different in sulfation pattern in terms
of positions and number of sulfates (1, 2). Since membrane
HSPG regulate cell proliferation, adhesion, migration, and
differentiation (3, 4), they are considered key players in cancer
cell development (1). This is because GAG chains of HSPG
interact with a large number (>435) of extracellular regulatory
proteins, such as growth factors, chemokines, and morphogens
(5). Indeed, drugs directed against HSPG are being evaluated
in preclinical models. For example, peptides directed against
syndecan-1 have shown therapeutic promise in preclinical
models of breast cancer and myeloma (6–8).
NT4 peptide is a tetrabranched peptide that binds to GAG
chains of HSPG. Its branched structure, obtained by synthesizing
four copies of the 13-amino-acid sequence on a branching
core of lysines, makes NT4 stable to proteolytic enzymes
and gives it a long half-life (9, 10). NT4 binds cell lines
of different human cancers, including colon adenocarcinoma,
pancreas adenocarcinoma, bladder cancer, and breast cancer
(11, 12). It does not bind PgsA-745 cells (Chinese hamster
ovary cell mutant), which lack GAG chains, being deficient in
xylosyltransferase, the enzyme responsible for anchorage of GAG
chains to the protein core (13). Tumor selectivity was very
evident in surgical resections of colon, pancreas, and bladder
cancer, stained with NT4 conjugated with a fluorescent probe,
compared to the healthy counterparts (14–16).
NT4 peptides can be conjugated with different functional
units and can selectively deliver drugs for cancer therapy or
transport tracers for tumor imaging (11, 12, 15–18). Using drug-
conjugated NT4, we obtained a significant reduction in tumor
growth or even tumor regression (11, 14, 17), compared to
animals treated with the unconjugated drug under identical
conditions. NT4 transports the chemotherapeutic moiety to the
cancer cell membrane and, ultimately, into the cell (14–16).
In animal models of cancer, the higher concentration of the
cytotoxic drug at the site of the tumor, obtained by the targeting
with the peptide, showed better efficacy than the free drug (11,
14, 17). We found that the high selectivity of NT4 toward cancer
cells and tissues resides in its high-affinity binding to sulfated
GAGs, with preferential high-affinity binding to heparin and
heparan sulfate (HS) compared to chondroitin sulfate (CS) (13,
19). Importantly, NT4 inhibited oriented migration of pancreas
adenocarcinoma cells (13) as well as growth factor-induced
migration and invasiveness of breast cancer cells, implying
antagonist binding to HSPG (13, 20).
Here, we report how the sulfation pattern of HSPG on cells can
drive binding specificity. Regardless the expression of different
HSPG on cancer cells, GAG linear polymers are the only exposed
HSPG moiety on the outer membrane and are responsible
for specificity.
The glycoside sequence and sulfation pattern of GAGs are
crucial for ligand binding and are synthesized by enzymes in
the Golgi apparatus and modified by extracellular enzymes
that can introduce recognition patterns for growth factors (2)
and other binding proteins. The specificity of GAG–ligand
interactions has been reported in several studies. For example,
it has been described in the case of the fibroblast growth factor
(FGF)–heparin interaction, where the key residues on FGF and
GAG chains were identified (21). The FGF–HS–FGFR1 ternary
complex can only be formed in the presence of 6-O-sulfate
groups on HS (22, 23). Interestingly, it has been observed
that short analogs of heparin, i.e., heparin oligosaccharides,
featuring one or two 6-O-sulfate groups on the reducing end
of glucosamine, can fully activate FGF2 signaling (24). 6-O-
sulfation of HS is also reported to be necessary to prompt
the response of primary fibroblasts to transforming growth
factor-β1 (TGFβ1), whereas 6-O-sulfates negatively regulateWnt
signaling (25, 26).
NT4 binds a specific pattern and competes with GAG binding
proteins for important biological functions like angiogenesis and
migration. As such, NT4was used here to define the fine structure
of binding sites on GAG chains.
METHODS
Peptide Synthesis
Peptides were synthesized on an automated multiple synthesizer
(MultiSynTech, Germany) by standard Fmoc chemistry. NT4
was synthesized on Fmoc4-Lys2-Lys-beta-Ala-Tentagel resin
(Rapp Polymer) using protected L-amino acids (Iris Biotech),
DIPEA (N,N-diisopropylethylamine) (Merck), and HBTU
(hexafluorophosphate benzotriazole-N,N,N’,N’-tetramethyl
uronium) (MultiSynTech). Pyro-Glu-O-pentachlorophenylester
(Bachem, Switzerland) was used for the last coupling step.
NT4-biotin was synthesized on Tentagel resin with Fmoc-
Lys(biotin)-OH as the first coupling step, and Fmoc-PEG12-OH
as the second; Fmoc-Lys(Fmoc)-OH was then used to build the
tetrameric core. At the end of the coupling sequence, peptides
were cleaved from the resin, deprotected, and lyophilized.
High-performance liquid chromatography (HPLC)
purification was performed on a C18 Jupiter column
(Phenomenex). Water with 0.1% trifluoroacetic acid (TFA)
(A) and methanol (B) were used as eluents. Linear gradients over
30min were run at flow rates of 0.8 and 4 ml/min for analytical
and preparatory procedures, respectively. All compounds were
also characterized on a BrukerUltraflex matrix-assisted laser
desorption/ionization time-of-flight/time-of-flight (MALDI
TOF/TOF) mass spectrometer.
NT4 (pyELYENKPRRPYIL)4K2K-beta-Ala MS: m/z
calculated for C333H519N91O81 [M+H]+ was 7,094.24;
detected 7,095.15. HPLC RT (from 80 to 20%A) 26.63min.
NT4-biotin (pyELYENKPRRPYIL)4K2K-PEG12-K(biotin) MS:
m/z calculated for C373H594N96O95S [M+H]+ was 7,976.35;
detected 7,978.72. HPLC RT (from 80 to 20%A) was 26.99 min.
Cell Lines
PANC-1 human pancreas adenocarcinoma, HT-29 human
colon adenocarcinoma, and MCF-7 and MDA-MB-231
human breast adenocarcinoma cells were grown in the
recommended American Type Culture Collection (ATCC)
media, supplemented with 10% fetal calf serum, 200µg/ml
glutamine, 100µg/ml streptomycin, 60µg/ml penicillin, and
maintained at 37◦C, 5% CO2. Cell lines were purchased from
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ATCC, and cell profiling was analyzed to authenticate human
cell lines (BMR Genomics).
Flow Cytometry
All experiments were performed using 2 × 105 cells in 96-well
U-bottom plates. All dilutions were performed in phosphate-
buffered saline (PBS), containing 5mM EDTA and 1% bovine
serum albumin (BSA).
NT4 Binding
Cells were incubated with 1µM NT4-biotin for 30min at room
temperature and then incubated with 1µg/ml streptavidin–
fluorescein isothiocyanate (FITC). For heparinase treatment,
cells were incubated for 1 h at 37◦C on the plates with 0.03
IU/ml heparinase I/III blend (Sigma Aldrich), and then harvested
and incubated with the same concentration of heparinase
in suspension for an additional hour at 37◦C before NT4
staining. All experiments were repeated two times. P values were
calculated using a two-tailed Student t-test and GraphPad Prism
5.0 software.
Real-Time Polymerase Chain Reaction
(qRT-PCR)
Total RNA samples were extracted from different human cancer
cells (1 × 106 cells) with TRIzol (Invitrogen, Milan, Italy). For
quantitative RT-PCR, RNA samples were retrotranscribed
using the High-Capacity cDNA Synthesis Kit (Applied
Biosystems, Monza, Italy) and amplified on an Abi Prism
7000 instrument (Applied Biosystems, Monza, Italy) using
the TaqMan Universal PCR Master Mix (Applied Biosystems)
following the manufacturer’s instructions.
The following human TaqMan gene expression
assays were used: glypican-3 GPC3 (Hs00170471_ml),
glypican-4 GPC4 (Hs00155059_m1), syndecan-3 SDC3
(Hs00206320_m1), syndecan-4 SDC4 (Hs00161617_m1), and
β-actin (Hs99999903_m1). Fluorescent signals generated during
PCR amplifications were monitored and analyzed with the Abi
Prism 7000 SDS software (Applied Biosystems). The following
PCR conditions were applied: 50◦C for 2min, 95◦C for 10min,
and 40 amplification cycles (95◦C for 15 s and 60◦C for 60 s).
In order to determine the efficiency of each TaqMan
gene expression assay, standard curves were generated by
serial dilution of cDNA, and quantitative evaluations of target
and housekeeping gene levels were obtained by measuring
threshold cycle numbers (Ct). A relative quantitative analysis was
performed, using the 2–11Ct value, where 1Ct = Ct (target)—
Ct (endogenous control) and 11Ct = 1Ct (sample)—1Ct
(calibrator). Beta actin was used as an endogenous control, and
the sample with the lowest expression was used as a calibrator
(syndecan-3 in HT-29).
Gene Expression of Human Sulfatases by
RT-PCR
PANC-1, HT-29, MDA-MB-231, and MCF-7 cells were
seeded in 6-well plates (5 × 105 cells per well) and cultured
overnight in a CO2 incubator. Total RNA was extracted
using an RNA isolation kit (Macherey-Nagel) according
to the manufacturer’s instructions. RNA was quantified
by spectrophotometry at 260 and 280 nm and verified by
agarose gel electrophoresis. The same quantity of RNA for
every cell line was loaded on the gel. One-step RT-PCR
(QIAGEN) was applied for retrotranscription and human
cDNA amplification of SULF-1 (393 pb) and SULF-2 (434 pb).
The following oligonucleotides were used as primers: SULF-1
primers, 5’-ACTTCCACTGCCTGCGTAATGA-3
′
(sense) and
5
′
-ATGAACGCTTTGAGGCTAGGCA-3
′
(antisense); SULF-2
primers, 5
′
-CCCAGAAGCTCACAAAGGAAAACG-3
′
(sense)
and 5
′
-AATGTCCACAACTGCGAGGGAT-3
′
(antisense).
The following PCR conditions were applied: for SULF-1, 30
denaturing cycles at 94◦C for 60 s, annealing at 58◦C for 60 s, and
extension at 72◦C for 90 s; for SULF-2, 30 denaturing cycles at
94◦C for 60 s, annealing at 54◦C for 60 s, and extension at 72◦C
for 60 s. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as experimental control. Signals were detected using
Image LAS4010 (GE Healthcare). Densitometry analysis was
carried out using ImageJ software. The value 100% corresponds
to GAPDH gene expression for each cell line. The experiment
was performed twice. P values were calculated using a one-tailed
Student t-test and GraphPad Prism 5.0 software.
Expression of Sulf-1
HT-29, PANC-1, MDA-MB-231, and MCF-7 cells were seeded
in 6-well plates (1.5 × 106 cells per well), previously
coated with 10µg/ml plasma fibronectin, and maintained
overnight in a CO2 incubator. Cells were lysed according to
the antibody supplier’s instructions (Abcam). Total proteins
(20 µl/lane) were separated with a 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to a nitrocellulose membrane (GE Healthcare). The
membrane was saturated with 5% w/v nonfat dry milk in PBS
containing 0.1% Tween20 for 1 h at room temperature and then
incubated with specific antibodies [rabbit polyclonal to sulfatase
1/SULF-1 antibody (1µg/ml, Abcam), and mouse anti-GAPDH
monoclonal antibody (1µg/ml, Invitrogen)]. After washing,
the membrane was incubated with horseradish peroxidase-
conjugated anti-rabbit IgG (1:2,000, Cell Signaling) in the
case of anti-sulfatase 1/SULF-1 antibody and with horseradish
peroxidase-conjugated anti-mouse immunoglobulin G (IgG)
(1:10,000, ThermoFisher). Signals were detected using Image
LAS4010 (GE Healthcare). Densitometry analysis was carried
out using ImageJ software. The value 100% corresponds to
average GAPDH protein expression for the four cell lines. The
experiment was performed three times. P values were calculated
using a parametric, unpaired Student t-test, and GraphPad Prism
5.0 software.
Surface Plasmon Resonance (SPR)
Experiments
Experiments were performed on a Biacore T100 instrument
(GE Healthcare). All materials were purchased from GE
Healthcare unless otherwise specified. Full-length recombinant
human HSPG were purchased from R&D Systems. Syndecan-
3, syndecan-4, and glypican-3 were obtained from the mouse
myeloma cell line (NS0), and glypican-4 was obtained from the
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Chinese Hamster Ovary cell line. The activity of syndecan-4,
glypican-3, and glypican-4 was measured by the supplier as the
ability of the immobilized protein to bind FGF-basic. The activity
of syndecan-3 was measured by the supplier as the ability of
the immobilized protein to inhibit adhesion of Saos-2 human
osteosarcoma cells to human fibronectin.
Eight-mer and nine-mer oligosaccharides S00
(GlcNAc-GlcA)4 α-paranitrophenyl, S04 (GlcNS-GlcA)4 α-
paranitrophenyl, S06a (GlcA-GlcNS)2-(GlcA-GlcNS,6S)2-GlcA
α-paranitrophenyl (9-mer), and S06b GlcNS-GlcA-GlcNS-
IdoA,2S-GlcNS-IdoA,2S-GlcNS-GlcA α-paranitrophenyl were
purchased from Iduron. In all oligosaccharides, the units
were linked together by α (1–4) bonds only and carry a
paranitrophenyl group. S12 (1HexA,2S α1-4 GlcNS,6S)3
(9-mer) was from Amsbio, and its first glycoside is unsaturated.
NT4-biotin was captured on a CM5 sensor chip where
streptavidin had previously been immobilized by standard
amine coupling. Briefly, the sensor chip surface was activated
with a mixture of 0.1M 1-ethyl-3(3-dimethylaminopropyl)-
carbodiimide (EDC) and 0.4M N-hydroxyl succinimide (NHS)
for 7min at a flow rate of 5µl/min. Streptavidin was injected over
the surface for 7min, and finally, 1M ethanolamine pH 8.5 was
used to block any activated carboxyl groups. NT4-biotin, diluted
in HBS-EP+ (Hepes 10mM, NaCl 150mM, EDTA 3.4mM,
0.05% p20, pH 7.4) to 30µg/ml, was injected for 2min at a flow
rate of 10 µl/min.
HSPG and oligosaccharides were diluted to different
concentrations in HBS-EP+ and then injected over immobilized
NT4 peptides. The sensor chip surface was regenerated with a
short pulse of 10mM NaOH/0.5M NaCl 5min after the end of
the injections.
Kinetics were analyzed with the Biacore T100 evaluation 1.1.1
software using the 1:1 Langmuir model to fit the curves.
Modeling of NT4-Sulfated Oligosaccharide
Complex
NT4 was modeled as extended conformation structure using
PyMOL (The PyMOL Molecular Graphics System, Version
1.4, Schrödinger, LLC) and refined by energy minimization
with the Gromacs package (27) and Amber force field
(28). The molecule was centered in a triclinic box with
at least 10-Å distance from the solute to the periodic box
border; the box was filled with TIP3P water model, and
the system was neutralized by adding counterions. A new
force field entry was created for lysine in the scaffold by
reparameterization of the standard lysine residue from the
Amber library, taking covalent bonding of the side-chain amine
into account. The peptide was linked to available amines of
the scaffold. The three-dimensional (3D) structure of the 8-
mer heparin oligosaccharide was derived from the canonical
helical structure of heparin (PDB ID 1HPN, 1C4 conformer)
(29). The GLYCAM06 force field parameters (30) were used
for GAGs.
RESULTS
In previous papers, we reported NT4 binding and internalization
into different cancer cell lines by immunofluorescence and flow
cytometry (11, 13, 14, 19). In previous confocal microscopy
experiments, NT4 conjugated with biotin (NT4-biotin) already
proved to be completely internalized only after 2 h at 37◦C
(14, 16). Degradation of NT4-biotin by living cells was previously
assessed by mass spectrometry and showed that the molecule
was still stable after 24 h (14). NT4 binding and internalization
into those cancer cells or tissues were completely inhibited by
heparin and HS (13, 19). We also demonstrated that NT4 binds
to heparin and HS with high affinity and to CS with lower
affinity (13).
To further assess the specificity of binding of the NT4 peptide
to HSPG in HT-29 colon adenocarcinoma, PANC-1 pancreas
adenocarcinoma, and MDA-MB-231 and MCF-7 breast cancer
human cell lines, we first treated the cells with the heparinase I/III
blend that removes HS from proteoglycans. We then incubated
the cells with NT4. Flow cytometry analysis showed that NT4
binding to cancer cells treated with heparinase was much lower
than to control cells (Figure 1).
FIGURE 1 | (A–D) NT4 binding to PANC-1, HT-29, MCF-7, and MDA-MB-231 cancer cells before and after heparinase I/III treatment, tested by flow cytometry. (E)
Variation of binding of NT4 after heparinase treatment, 100% (dark histogram) is the baseline binding of NT4 to the different cell lines ***p < 0.001, **p < 0.01,
*p < 0.05 by Student’s t-test.
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Gene Expression of Glypicans and
Syndecans in HT-29, PANC-1,
MDA-MB-231, and MCF-7 Cancer Cells
Glypican and syndecan levels have recently been studied with a
view to defining new tumor markers or prognostic tools (6, 31).
Elevated levels of glypican-1 are found in pancreas carcinoma
where increased expression is associated with poor prognosis
(32). Levels of glypican-1 and syndecan-2 are also increased
in colorectal cancer (1). Breast cancer was found to upregulate
glypican-1 (33–35) and syndecan-4 (36) and to downregulate
glypican-3 (37), while loss of glypican-3 promotes tumor
proliferation and metastasis (38). Glypican-2 is upregulated
in neuroblastoma and associated with poor overall survival
(1). The roles of glypican-4 and syndecan-3 in tumors are
still underexplored.
Figure 2 shows syndecans and glypicans expression in HT-29,
PANC-1, MDA-MB-231, and MCF-7 as analyzed by qRT-PCR.
Expression of syndecans (Figure 2, shades of green) was
generally higher than that of glypicans (Figure 2, shades of blue).
Among syndecans, syndecan-4 was the most expressed in all
cell lines, followed by syndecan-3 in MCF-7, MDA-MB-231,
and PANC-1 cells. Among glypicans, glypican-4 was the most
expressed, but only in MCF-7 cells (Figure 2).
Sulfatases Modulate NT4 Binding on
Cancer Cells
Human sulfatase 1 (hSULF-1) and human sulfatase 2 (hSULF-
2) are extracellular enzymes that remove 6-O-sulfate groups
from HS chains. Modified expression of both sulfatases,
particularly SULF-1, has been associated with different cancers
(38). By hydrolyzing 6-O-sulfate groups, hSULF-1 and hSULF-2
modulate binding of HS-binding proteins, such as growth factors
and cytokines, and, finally, have effects on cell signaling (38).
For example, hSULF-1, acting on HS, reduces the formation of
the FGF2–FGFR–HS complex and consequently impairs FGF2
signaling (39).
Figure 3A shows the relative abundance of mRNA of hSULF-
1 and hSULF-2 in HT-29, PANC-1, MCF-7, and MDA-MB-
231 cells as measured by RT-PCR. The two sulfatases were
expressed very differently in the different cell lines. SULF-1
protein expression was also measured in the same cell lines using
a specific anti-SULF-1 antibody (Figure 3B). PANC-1 and HT-29
cells showed much lower expression of sulfatases, which implies
that their sulfated GAG chains retain more 6-O-sulfate groups
than cancer cells with higher expression of sulfatases, such as
MCF-7 and MDA-MB-231.
The pattern of NT4 cell binding detected by flow cytometry
(Figure 3C) suggests that cells expressing lower levels of
sulfatases, particularly SULF-1, such as PANC-1 and HT-29, bind
NT4 better than the others. The higher presence of the 6-O-
sulfate groups is therefore correlated with higher binding of NT4
to those cell lines.
Affinity of NT4 for Recombinant HSPG and
Sulfated GAGs
We used SPR to measure the affinity of NT4 binding to
recombinant syndecans and glypicans, selected among those
highly expressed by HT-29, PANC-1, MDA-MB-231, and MCF-7
cancer cell lines. We found that NT4 does not bind syndecan-
3, whereas it binds syndecan-4, glypican-3, and glypican-4
(Figures 4A–D) with different affinities, the affinity of both
glypicans being five times greater than that of syndecan-4.
SPR analysis also enabled kinetic evaluation of NT4 binding
to HSPG, showing different kinetic rates of association and
dissociation (Table 1).
Binding of NT4 to synthetic oligosaccharides carrying
different sulfation patterns was also analyzed. We used 8-mer
and 9-mer oligosaccharides with different sulfation patterns: no
sulfation in oligosaccharide S00, 4 N-sulfate groups in S04, 6
sulfate groups in S06a including 4 N-sulfates and 2 6-sulfates, 6
FIGURE 2 | Gene expression of human glypicans (shades of blue) and syndecans (shades of green) in HT-29, PANC-1, MCF-7, and MDA-MB-231 human cancer cell
lines determined by qRT-PCR and normalized against β-actin. Results are reported as fold change for syndecan-3 in HT-29.
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FIGURE 3 | (A) Gene expression of hSULF-1 and hSULF-2 in HT-29, PANC-1, MCF-7, and MDA-MB-231 cell lines analyzed by RT-PCR. The GAPDH gene was tested
as endogenous control. Histograms represent percentage of gene expression compared to GAPDH (GAPDH is 100%). (B) SULF-1 expression analyzed by Western
blot in the same cell lines. Histograms represent percentage of SULF-1 expression compared to GAPDH (GAPDH is 100%). Significance of the differences was
calculated using Student’s t-test and GraphPad, **p < 0.01; ***p < 0.001. (C) NT4 binding analyzed by flow cytometry in HT-29, PANC-1, MCF-7, and MDA-MB-231.
sulfate groups in S06b including 4 N-sulfates and 2 2-O-sulfates,
and, finally, 12 sulfate groups in S12, 4 in 6-O-position, 4 in
2-O, and 4 in N. We observed that the more sulfate groups
there were, the higher was the affinity of the oligosaccharide
for the peptide. We also found a correlation between sulfation
in position 6 of oligosaccharides and NT4 binding affinity.
Indeed, S06a, which carries the same number of sulfates as
S06b, bound NT4 better by virtue of having two 6-O-sulfates
(Figure 4). The best-binding oligosaccharide was S12, which
carries repeated 6-O-sulfates, like S06a, but the 6-O-sulfates in
S12 are alternated with 2-O or N-sulfates, making binding more
stable (Table 1).
Graphical Model of Interaction of NT4 and
a Sulfated Oligosaccharide
NT4 was modeled with PyMol and refined by energy
minimization. The 3D structure of the positively charged
stretch of the NT4 peptide sequence (K6PRRP10), previously
demonstrated to be critical for heparin binding (19), resulted in
an extended conformation that lowers steric hindrance between
rigid prolines and their preceding amino acids bearing a large
side chain. This conformation gives rise to a triangular pattern
formed by the charged termini of K6, R8, and R9, with 6–8
and 8–9 distances of ∼12 Å and an angle of ∼130◦ between
residues 6–8–9.
The 8-mer oligosaccharide was chosen for the in silico study
on the basis of the experimental result obtained with flow
cytometry that identified S12 (12 sulfate groups in an 8-mer)
as the best-binding oligosaccharide, and its 3D structure was
derived from the canonical helical structure of heparin (PDB ID
1HPN, 1C4 conformer) (29).
Previous studies showed that the binding of heparin and
HS to polypeptides is ionic in nature (40–42). The charge-
based interactions between the acidic substituents on the
polysaccharide and basic residues on the polypeptide are
reported to dominate the interface, and charges have to
be in an appropriate 3D pattern (43). For example, FGF1
proved to prefer a specific pattern of sulfate groups in a
specific spatial distribution (44). Following such evidences, a
matching between charge clusters was attempted by mean of 3D
molecular graphics.
Indeed, the sulfates of GlcNSi−3-IdoA2Si-GlcNS6Si+1
(corresponding to GlcN2-IdoA5-GlcN6 and GlcN4-IdoA7-
GlcN8), lying on the same side of the helix, form a pattern with
distances and angles coherent with those of charged side chains
of KPRR, and a specific geometry of interaction of charges is
suggested (yellow dashed lines in Figure 5). Similar results hold
for the 1C4 and 2S0 cyclic forms of the oligosaccharide. On
an 8-mer saccharide, this pattern is found twice on opposite
sides of the helix, possibly interacting with two different NT4
peptide arms.
This interaction model also explains the almost total loss of
binding for S04 (N-sulfates only), where alternate side sulfates are
unable to form any negative charge cluster (Figure 5) that could
fit with the positive cluster of NT4.
The in silico modeling provides a theoretical picture of the
interaction that can help in understanding the binding activity
of NT4. In particular, the fact that the oligosaccharide has
two negative clusters on opposite sides of the molecule could
reinforce the hypothesis of multiple binding with NT4.
DISCUSSION
HSPG are synthesized by most animal cells, but due to the
variable composition and sulfation of their GAG chains, their
ability to interact with specific ligands may be modulated
under different physiological and pathological conditions,
including cancer. Tumor stroma is composed of the ECM,
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FIGURE 4 | SPR analysis of rHSPG and oligosaccharide binding to NT4. (A) rHSPG binding (25µg/mL) to immobilized NT4. (B–D) Affinity of rHSPG for NT4. (E)
Oligosaccharide (100µg/ml) binding to surface immobilized NT4. (F) Schematic representation of oligosaccharides with sulfation sites. (G) Affinity of S12 sulfated
oligosaccharide binding to NT4. (H) Structure of S12.
including proteoglycans, fibronectin, collagen, cytokines, and
growth factors. Cells that populate the tumor stroma, like
immune system cells, fibroblasts, and endothelial cells, together
with tumor cells, can modify the stroma as the tumor
evolves. The ECM of the tumor stroma is very different
from that of normal tissues (1) due to tumor remodeling
that also triggers tumor invasiveness (1). HSPG accumulate
in remodeled stroma and are, in turn, modified on their
glycosidic chains by tumor-dependent glycosyltransferases,
sulfotransferases, sulfatases, and heparanases (6, 45). The
presence and amount of these GAG-related enzymes help
identify high-risk tumors and develop targeting therapies (46).
In colon tumors, for example, significant upregulation of
extracellular sulfatases SULF-1/2 has been observed and may
indicate general alteration of HS 6-O-sulfation patterns in colon
tumors (47).
As discussed in the introduction, hundreds of different
extracellular regulatory proteins, such as growth factors,
chemokines, and morphogens, also involved in cancer, interact
with the GAG portion of HSPG, requiring specific glycosides
sequences and sulfation patterns (23).
The peculiar post-translationally regulated variability of
HSPG has made it difficult to study their activity in cancer
cell biology.
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NT4 is already known to have major effects on cancer cells,
such as inhibition of migration and invasion of ECM induced by
FGF (20).
We examined the expression of syndecans and glypicans
in a panel of cancer cell lines that NT4 binds. The
binding affinity of NT4 with human rHSPG expressed
TABLE 1 | Kon, koff, and KD of recombinant glypicans and syndecans and
oligosaccharides.
Ka (M−1s−1) Kd (s−1) KD (M)
Syndecan-4 0.901E+4 23.16E−4 2.570E−7
Glypican-3 2.392E+4 14.33E−4 5.989E−8
Glypican-4 0.871E+4 6.719E−4 7.708E−8
S06a 0.106E+4 25.75E−4 2.427E−6
S06b 0.149E+4 40.39E−4 2.700E−6
S12 0.353E+4 9.126E−4 2.578E−7
by these cells was then analyzed by SPR. NT4 did not
bind syndecan-3, but it bound glypican-3 and -4, and
also syndecan-4, but with one fifth of the affinity shown
for glypicans.
Glypicans and syndecans have different GAG chains:
glypicans only carry HS chains, whereas syndecans-2 and 4
have HS chains and syndecans-1 and 3 have HS and CS
chains (4, 48). Besides, HS posttranslational modifications
occur in clusters, i.e., HS has some domains that are more
densely sulfated than others. For example, the FGF binding
domain that has 2-, 6-, and N-sulfation, carries seven sulfated
groups in five residues, whereas the anti-thrombin binding
domain contains six sulfated groups in five residues. In
contrast, CS has more homogeneously sulfated patterns with
long tracts carrying an average of four sulfates every five
residues (49).
The NT4 affinity profile is therefore consistent with our
previous results that showed a preference of the peptide for HS
chains featuring patches of dense sulfation, compared to CS (49).
FIGURE 5 | NT4-sulfated oligosaccharide hypothetical complex. (A) Model of NT4 complexed with the 8-mer sulfated oligosaccharide. Clusters of sulfates on both
sides of the helical structure of the oligosaccharide are identified by pale blue lines, with the sulfates involved represented as spheres. Polar interactions between the
positive charges on peptide residues and sulfate negative clusters are drawn as dashed yellow lines. (B) Model of NT4 structure with KPRR motifs in pale blue. (C)
Structure of the sulfated oligosaccharide (29).
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Another important finding regarding NT4 recognition of
sulfated GAG chains came from the analysis of sulfatase
expression in the same panel of human cancer cell lines. NT4
binding to the cancer cell membrane was inversely correlated
with expression of sulfatases. NT4 binding was higher in cell lines
with lower expression of sulfatases, particularly SULF-1, i.e., HT-
29 and PANC-1, confirming the determinant role of 6-O-sulfate
groups for recognition by NT4.
Using 8-mer and 9-mer HS oligosaccharides with analog
disaccharide composition and different sulfation sites, a possible
recognition motif was identified that includes repeated 6-O-
sulfates alternating with N- and/or 2-O-sulfates. This finding
is again consistent with the preference of NT4 for HS more
than for CS. CS carries GAG chains with 2-O-sulfates and
4-O-sulfates, whereas HS has 6-O-sulfates alternating with
N- or 2-O-sulfates.
The possible structure of the NT4-sulfated oligosaccharide
complex was then reconstructed by molecular modeling, taking
into account our information on amino acids in NT4 sequences,
i.e., KPRR, previously demonstrated to be essential for heparin
and HS binding (13, 19). The modeling showed that the
distance between the crucial positive residues of NT4 is
completely compatible with ionic interaction with sulfates on
the oligosaccharide. Moreover, assuming a helical structure
of the oligosaccharide, which is considered usual for sulfated
oligosaccharides, sulfate groups lying on opposite sides of the
helix can interact with positive residues on two peptide sequences
of the branched structure, thus favoring multivalent binding,
and explaining the high affinity and selectivity of NT4 for
highly sulfated GAGs. Being a branched peptide, NT4 can give
multiple binding to repeated domains on the same GAG chain
or on different GAG chains of the same HSPG, improving
binding affinity. Specificity of GAG ligand binding, which allows
formation of the GAG–ligand–receptor complex that triggers
signal transduction, is mediated by multivalent electrostatic
interactions between GAGs and growth factors or proteins of
the ECM. The presence of binding sites of growth factors
and proteins on GAG chains is no longer disputed, and the
exact structure and motifs of the recognition patterns are being
explored (23, 50, 51).
NT4 and possibly newly selected branched peptides can be
designed and used to unravel the exact structure of binding
sites on GAG chains. These tools will be essential probes
for reconstructing binding sites for cancer-involved ligands
on GAGs, paving the way for new cancer detection and
treatment options.
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